Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

VIP cycle length: what human studies ran

InvestigationalAHuman trial evidence
Short answer: there is no established VIP cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. Both intravenous COVID-19 trials administered aviptadil as 12-hour infusions on three successive days; the first followed participants to day 60 and TESICO assessed the primary outcome at day 90, with mortality followed to day 90 1,2.
  2. The inhaled COVID-19 trial administered inhalations for a minimum of 7 and a maximum of 14 days, discontinuing at 14 days if symptoms had not improved, with eight scheduled visits and assessment of CT lung damage score to day 28 9.
  3. The pulmonary hypertension study used a single inhaled dose during catheterisation 10; the sarcoidosis study nebulized VIP for 4 weeks 11.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • VIP combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established VIP cycle length?
No. Human studies administered VIP for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of VIP?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
VIP dosing reference Full research page

References

  1. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial Critical Care Medicine. 2022
  2. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial The Lancet Respiratory Medicine. 2023
  3. Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review Respiratory Research. 2011
  4. Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis Indian Journal of Critical Care Medicine. 2025
  5. openFDA drug label, Drugs@FDA and NDC directory queries for aviptadil, ZYESAMI and vasoactive intestinal peptide openFDA. 2026
  6. Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial) (NCT06729606), with related records NCT04843761, NCT04453839 and NCT03556020 ClinicalTrials.gov. 2022
  7. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated May 14, 2026) FDA. 2026
  8. World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026
  9. Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19 Med Princ Pract. 2025
  10. Inhalation of vasoactive intestinal peptide in pulmonary hypertension Eur Respir J. 2008
  11. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis Am J Respir Crit Care Med. 2010